Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset

Volume: 50, Issue: 12, Pages: 2025 - 2040
Published: Nov 10, 2020
Abstract
SARS‐CoV‐2 has emerged as a human pathogen, causing clinical signs, from fever to pneumonia—COVID‐19—but may remain mild or asymptomatic. To understand the continuing spread of the virus, to detect those who are and were infected, and to follow the immune response longitudinally, reliable and robust assays for SARS‐CoV‐2 detection and immunological monitoring are needed. We quantified IgM, IgG, and IgA antibodies recognizing the SARS‐CoV‐2...
Paper Details
Title
Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset
Published Date
Nov 10, 2020
Volume
50
Issue
12
Pages
2025 - 2040
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.